Ultragenyx Pharmaceutical Inc. (RARE) earnings date
Feb 11, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 67% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 4 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Tue, Nov 3, 2026 | after close | 34 | 8-K |
| Q2 FY2026 | Tue, Aug 4, 2026 | after close | 35 | 8-K |
| Q1 FY2026 | Tue, May 5, 2026 | after close | 35 | 8-K |
| Q4 FY2025 | Thu, Feb 12, 2026 | after close | 43 | 8-K |
| Q3 FY2025 | Tue, Nov 4, 2025 | after close | 35 | 8-K |
| Q2 FY2025 | Tue, Aug 5, 2025 | after close | 36 | 8-K |
| Q1 FY2025 | Tue, May 6, 2025 | after close | 36 | 8-K |
| Q4 FY2024 | Thu, Feb 13, 2025 | after close | 44 | 8-K |
What they guided beta
| Q3 FY2026 | "EX-99.1 Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa ir@ultragenyx.com Media Jess Rowlands media@ultragenyx.com Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027 Third quarter total revenue of $173 million, CRYSVITA® revenue of $109 million and DOJOLVI® revenue of $30 million GENGLYCOS™ and FAYUVI™ BLAs approved by FDA in the third quarter Two Priority Review Vouchers (PRVs) under agreement for combined sales price of $413 million Substantial reduction of expenses and hea" exhibit |
| Q3 FY2026 | "NOVATO, Calif. – November 03, 2026 – Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter ended September 30, 2026, announced substantial expense reductions, and reaffirmed its guidance for 2026 revenue and 2027 profitability." exhibit |
| Q3 FY2026 | "“With substantial reductions in headcount and expenses, combined with two launches and continued growth in our base business, we expect meaningful profitability in 2027 and going forward.”" exhibit |
| Q3 FY2026 | "Third Quarter 2026 Revenue Highlights and 2026 Revenue Guidance" exhibit |
| Q3 FY2026 | "The company reaffirms its full year 2026 total revenue guidance of $730 million to $760 million, which excludes revenue from new product launches." exhibit Read from the sentence: revenue $730 million to $760 million, FY2026 |
| Q2 FY2026 | "EX-99.1 Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa ir@ultragenyx.com Media Jess Rowlands media@ultragenyx.com Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update Second quarter total revenue of $214 million, Crysvita® revenue of $156 million and Dojolvi® revenue of $27 million Reaffirm 2026 financial guidance, including total revenue of $730 million to $760 million and combined R&D and SG&A expenses to be flat to slightly down versus 2025; remain on path to profitability in 2027 Catalysts in second half of 2026 include two PDUFA" exhibit |
| Q2 FY2026 | "“In the second quarter we generated the highest quarterly revenue in the history of the company, supporting our full-year revenue guidance, and keeping us on track toward profitability in 2027,” said Emil D." exhibit |
| Q2 FY2026 | "Second Quarter 2026 Revenue Highlights and 2026 Revenue Guidance" exhibit |
| Q2 FY2026 | "The company reaffirms its full year 2026 total revenue guidance of $730 million to $760 million, which excludes revenue from potential new product launches." exhibit Read from the sentence: revenue $730 million to $760 million, FY2026 |
| Q2 FY2026 | "Crysvita revenue in the second quarter of 2026 was $156 million, consistent with expected seasonality in the U.S. and Canada and ordering patterns in Latin America." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/RARE
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/RARE
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/RARE/"><img src="https://veritasdata.dev/embed/RARE.svg" alt="RARE earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/RARE/)
Script
<script async src="https://veritasdata.dev/embed/RARE.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/RARE"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.